Overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy according to their participation (or not) in clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback